Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Metavia Inc (MTVA)

Metavia Inc (MTVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,544
  • Shares Outstanding, K 2,201
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,590 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.06
  • Number of Estimates 2
  • High Estimate -1.82
  • Low Estimate -2.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4300 +11.19%
on 02/19/26
2.8699 -44.60%
on 02/02/26
-1.2200 (-43.42%)
since 01/26/26
3-Month
1.4300 +11.19%
on 02/19/26
13.4200 -88.15%
on 12/08/25
-6.6622 (-80.73%)
since 11/26/25
52-Week
1.4300 +11.19%
on 02/19/26
23.1000 -93.12%
on 04/15/25
-15.0200 (-90.43%)
since 02/26/25

Most Recent Stories

More News
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

CAMBRIDGE, Mass. , Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung...

MTVA : 1.5900 (-1.24%)
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further

MTVA : 1.5900 (-1.24%)
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

DeepMatcher ® Platform Confirms Strong Inflammatory and Cardiometabolic Target Engagement, Supporting Development in MASH and Potential Type 2 Diabetes

MTVA : 1.5900 (-1.24%)
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

CAMBRIDGE, Mass. , Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,...

MTVA : 1.5900 (-1.24%)
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

CAMBRIDGE, Mass. , Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc.  (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,...

MTVA : 1.5900 (-1.24%)
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54

MTVA : 1.5900 (-1.24%)
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

CAMBRIDGE, Mass. , Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it...

MTVA : 1.5900 (-1.24%)
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ --  MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that...

MTVA : 1.5900 (-1.24%)
MetaVia Inc. Announces 1-for-11 Reverse Stock Split

CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (" MetaVia " or the " Company "), a clinical-stage biotechnology company focused on transforming cardiometabolic...

MTVA : 1.5900 (-1.24%)
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles

MTVA : 1.5900 (-1.24%)

Business Summary

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.7133
2nd Resistance Point 1.6767
1st Resistance Point 1.6333
Last Price 1.5900
1st Support Level 1.5533
2nd Support Level 1.5167
3rd Support Level 1.4733

See More

52-Week High 23.1000
Fibonacci 61.8% 14.8221
Fibonacci 50% 12.2650
Fibonacci 38.2% 9.7079
Last Price 1.5900
52-Week Low 1.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar